SURPASS-4 trial: Tirzepatide slows rate of eGFR decline and reduces UACR in T2DM patients
An analysis of the SURPASS-4 trial has reported that type 2 diabetics with high cardiovascular risk who took resulted in a slowed the...
top of page
Browse by category
Search
Browse by tag
bottom of page